Quickly find freely available drug and population models in our PBPK model repository.
The models provided have been collated from published examples which authors have shared in our Published Model Collection or developed as part of various global health projects in our Global Health Collection. This search facility searches both model collections simultaneously.
To contribute published user compound and/or population files, upload your files here: Upload Model Files
This is compound file for tizanidine, a CYP1A2 substrate. The input values for the Tizanidine PBPK model are listed in table 1 of the publication. The file uses a User fugut of 1E-06. A solid formulation is used with the segregated transit time model activated and a predicted aqueous phase intrinsic solubility.
Tramadol adult compound file for pediatric prediction. The following parameters need to be updated, as compared to Table 2 in the manuscript: CYP2D6 0.7, CYP3A4 0.035, CYP2B6 0.1, CLr 6.6 L/hr
Brand Name(s) include: N/A
Disease: Malaria
Drug Class: Antimalarials
Date Updated: March 2022
Related drugs: Proguanil
Absorption Model |
First-Order |
Volume of Distribution |
Full PBPK (Method 2) |
Route of Elimination |
Formed by CYP2C19, CYP3A4; unknown clearance mechanism |
Perpetrator DDI |
|
Validation |
|
Limitations |
|
Updates in V19 |
|
Brand Name(s) include: Viracept
Disease: HIV
Drug Class: Protease Inhibitor
Version: 21
Date Updated: March 2023
Absorption Model |
ADAM (Solution) |
Volume of Distribution Details |
Full PBPK (Method 2) |
Route of Elimination |
|
Perpetrator DDI |
|
Validation |
The refined model was able to recover clinically observed concentration-time profiles of nelfinavir following single and multiple dosing. Six clinical DDI studies where nelfinavir was administered with either ritonavir, rifampicin, rifabutin, efavirenz, and nevirapine were used to verify the PBPK model of nevirapine as a victim. In comparison of predicted vs. observed AUC, 100% of the studies were within 1.5-fold. Nine clinical DDI studies where nevirapine was administered with either alfentanil, midazolam, simvastatin, atorvastatin, rifabutin, or digoxin were used to verify the PBPK model of nevirapine as a perpetrator. In comparison of predicted vs. observed AUC, 100% of the studies were within 2-fold and 78% were within 1.25-fold. |
Limitations |
|
14 |